^
    Back
    Association details:
    Biomarker:KDM6A mutation
    Cancer:Urothelial Cancer
    Drug:Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.

    Published date:
    05/25/2023
    Excerpt:
    MVA of this large, multi-site, retrospective cohort of aUC pts, identified several putative biomarkers independently associated with EV treatment outcomes. Longer OS was associated with ERBB2 and KDM6A alts, low PD-L1 and high TMB.
    DOI:
    10.1200/JCO.2023.41.16_suppl.4573